Attorney User
Education
2007
Dissertation Title: "Development of Topoisomerase I Inhibitors as Therapeutic Agents"
Awards & Honors
Giles Rich Intellectual Property Moot Court Competition, Boston Regional – Best Appellate Brief & Best Appellee Brief (2010)
Dr. Lawrence Cranberg Scholarship Endowment in Science and Law (2007)
American Chemical Society Division of Medicinal Chemistry Pre-doctoral Fellowship (2005)
American Foundation for Pharmaceutical Education Fellowship (2005)
National Cancer Institute Training Grant for DNA-Drug Interactions (2002-2005)
Purdue University Andrew’s Fellowship (2002)
American Chemical Society Northeast Tennessee Regional Award (2001)
Energy Research Undergraduate Laboratory Fellowship, Oak Ridge National Laboratory (1999, 2001)
Research Experience for Undergraduates, University of Kansas, Lawrence, KS (2000)
Telephone
202-640-6400
Office Location(s)
Professional Profile
Andrew E. Morrell, Ph.D. is an associate in our Washington DC office.
Dr. Morrell is a registered patent attorney who regularly counsels clients on drug development and litigates cases under the Hatch-Waxman Act. He also represents clients before the U.S. Patent and Trademark Office in post-grant proceedings and interferences.
Dr. Morrell earned his J.D. from George Mason University and was a member of the Intellectual Property Law Society. Prior to law school, Dr. Morrell earned his Ph.D. from Purdue University, where his research focused on the synthesis and biological evaluation of topoisomerase I inhibitors as anticancer agents. As a post-doctoral associate at Purdue University, Dr. Morrell studied the incorporation of heterocycles in the indenoisoquinoline class of topoisomerase I inhibitors, as well as the design and synthesis of indenoisoquinoline/camptothecin chimeras.
Dr. Morrell joined the firm in 2010 and was previously an associate in the San Diego office. From 2014 top 2015, Dr. Morrell worked for Mylan Inc. providing patent counsel for generic drug development, ANDA submissions, and product launches.
Specializing In
Cases, Articles, Speeches & Seminars
Articles
Condo-Sheridan, M.; Reddy, P.V.; Morrell, A.; Cobb, B.; Marchand, C.; Agama, K.; Chergui, A.; Renaudt, A.; Stephen, A.; Bindu, L., Pommier, Y.; Cushman, M. Synthesis and Biological Evaluation of Indenoisoquinolines That Inhibit Both Tyrosyl-DNA Phosphodiesterase I (Tdp1) and Topoisomerase I (Top1). J. Med. Chem. 2013, 56(1), 182-200.
Chen, L.; Conda-Sheridan, M.; Reddy, P.V.; Morrell, A.; Park, E.J.; Kondratyuk, T.P.; Pezzuto, J.M.; van Breemen, R.B.; Cushman, M. Identification, Synthesis, and Biological Evaluation of the Metabolites of 3-Amino-6-(3'-aminopropyl)-5H-indeno[1,2-c]isoquinoline-5,11-(6H)dione (AM6-36), a Promising Rexinoid Lead Compound for the Development of Cancer Chemotherapeutic and Chemopreventive Agents. J. Med. Chem. 2012, 55(12), 5965-5981.
Nguyen, T.X.; Morrell, A.; Conda-Sheridan, M.; Marchand, C.; Agama, K.; Bermingam, A.; Stephen, A.G.; Chergui, A.; Naumova, A.; Fisher, R.; O'Keefe, B.R.; Pommier, Y.; Cushman, M. Synthesis and biological evaluation of the first dual tyrosyl-DNA phosphodiesterase I (Tdp1)-topoisomerase I (Top1) inhibitors. J. Med. Chem. 2012, 55(9), 4457-4478.
Kiselev, E.; DeGuire, S.; Morrell, A.; Agama, K.; Dexheimer, T.S.; Pommier, Y.; Cushman, M. 7-Azaindenoisoquinolines as topoisomerase I inhibitors and potential anticancer agents. J. Med. Chem. 2011, 54(17), 6106-6116.
Peterson, K.E.; Cinelli, M.A.; Morrell, A.E.; Mehta, A.; Dexheimer, T.S.; Agama, K.; Antony, S.; Pommier, Y.; Cushman, M. Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase I inhibitors: investigating the relationships involving stereochemistry, hydrogen bonding, and biological activity. J. Med. Chem. 2011 54(14), 4937-4953.
Park, E.J.; Kondratyuk, T.P.; Morrell, A.; Kiselev, E.; Conda-Sheridan, M.; Cushman, M.; Ahn, S.; Choi, Y.; White, J.J.; van Breemen, R.B.; Pezzuto, J.M. Induction of retinoid X receptor activity and consequent upregulation of p21WAF1/CIP1 by indenoisoquinolines in MCF7 cells. Cancer Prev. Res. (Phila). 2011 4(4), 592-607
Marler, L.; Conda-Sheridan, M.; Cinelli, M.A.; Morrell, A.E.; Cushman, M.; Chen, L.; Huang, K.; Van Breemen, R.; Pezzuto, J.M. Cancer chemopreventive potential of aromathecins and phenazines, novel natural product derivatives. Anticancer Res. 2010,
30(12), 4873-4882.
Cinelli, M.; Morrell, A.; Dexheimer, T.; Agama, K.; Agrawal, S.; Pommier, Y.; Cushman, M. The Structure-activity Relationships of A-ring-substituted Aromathecin Topoisomerase I Inhibitors Strongly Support a Camptothecin-like Binding Mode. Bioorg. Med.
Chem. 2010, 18, 5535-5552.
Bakshi, R. P.; Sang, D.; Morrell, A.; Cushman, M.; Shapiro, T. A. Activity of Indenoisoquinolines Against African Trypanosomes. Antimicrob. Agents Chemother. 2009, 53, 123-128.
Cinelli, M.; Morrell, A.; Dexheimer, T.; Pommier, Y.; Cushman, M. Design, Synthesis, and Biological Evaluation of 14- Substituted Aromathecins as Topoisomerase I Inhibitors. J. Med. Chem. 2008, 51, 4609-4619.
Antony, S.; Agama, K.; Miao, Z.-H.; Takagi, K.; Wright, M.; Robles, A.; Varticovski, L.; Robey, R.; Bates, S.; Nagarajan, M.; Morrell, A.; Cushman, M.; Pommier, Y. Novel Indenoisoquinolines NSC 725776 and NSC 724998 Produce Persistent Topoisomerase I Cleavage Complexes and Overcome Multidrug Resistance. Cancer Res. 2007, 67, 10397-10405.
Morrell, A.; Placzek, M.; Parmley, S.; Antony, S.; Dexheimer, T.; Pommier, Y.; Cushman, M. Nitrated Indenoisoquinolines as Topoisomerase I Inhibitors: A Systematic Study and Optimization. J. Med. Chem. 2007, 50, 4419-4430.
Morrell, A.; Placzek, M.; Parmley, S.; Grella, B.; Antony, S.; Pommier, Y.; Cushman, M. Optimization of the Indenone Ring of
Indenoisoquinoline Topoisomerase I Inhibitors. J. Med. Chem. 2007, 50, 4388-4404.
Morrell, A.; Placzek, M.; Steffen, J.; Antony, S.; Agama, K.; Pommier, Y.; Cushman, M. Investigation of the Lactam Side Chain Length Necessary for Optimal Indenoisoquinoline Topoisomerase I Inhibition and Cytotoxicity in Human Cancer Cell Cultures.
J. Med. Chem. 2007, 50, 2040-2048.
Morrell, A.; Antony, S.; Kohlhagen, G.; Pommier, Y.; Cushman, M. A Systematic Study of Nitrated Indenoisoquinolines Reveals
a Potent Topoisomerase I Inhibitor. J. Med. Chem. 2006, 49, 7740-7753.
Nagarajan, M.; Morrell, A.; Ioanoviciu, A.; Antony, S.; Kohlhagen, G.; Hollingshead, M.; Pommier, Y.; Cushman, M. Synthesis and Evaluation of Indenoisoquinoline Topoisomerase I Inhibitors Substituted with Nitrogen Heterocycles. J. Med. Chem. 2006,
49, 6283-6289.
Morrell, A.; Antony, S.; Kohlhagen, G.; Pommier, Y.; Cushman, M. Synthesis of Benz[d]indeno[1,2-b]pyran-5,11-diones: Versatile Intermediates for the Design and Synthesis of Topoisomerase I Inhibitors. Bioorg. Med. Chem. Lett. 2006, 16, 1846-
1849.
Morrell, A.; Jayaraman, M.; Nagarajan, M.; Fox, B.M.; Meckley, M.R.; Ioanoviciu, A.; Pommier, Y.; Antony, S.; Hollingshead, M.;
Cushman, M. Evaluation of Indenoisoquinoline Topoisomerase I Inhibitors Using a Hollow Fiber Assay. Bioorg. Med. Chem. Lett. 2006, 16, 4395-4399.
Nagarajan, M.; Morrell, A.; Antony, S.; Kohlhagen, G.; Agama, K.; Hollingshead, M.; Pommier, Y.; Cushman, M. Synthesis and
Biological Evaluation of Bisindenoisoquinolines as Topoisomerase I Inhibitors. J. Med. Chem. 2006, 49, 5129-5140.
Xiao, X.; Morrell, A.; Fanwick, P.E.; Cushman, M. On the Mechanism of Conversion of 4-Carboxy-3,4-dihydro-3-phenyl-1(2H)-
isoquinolones to Indeno[1,2-c]isoquinolines by Thionyl Chloride. Tetrahedron 2006, 62, 9705-9712.
Antony, S.; Agama, K.; Miao, Z.; Hollingshead, M.; Wright, M.; Varticovski, L.; Nagarajan, M.; Morrell, A.; Cushman, M.; Pommier, Y. Bisindenoisoquinoline NSC 727357, a DNA bisintercalator and topoisomerase inhibitor with antitumor activity. Mol. Pharmacol. 2006, 70, 1109-1120.
Morrell, A.; Antony, S.; Kohlhagen, G.; Pommier, Y.; Cushman, M. Synthesis of Nitrated Indenoisoquinolines as Topoisomerase I Inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 3659-3663.
Nagarajan, M.; Morrell, A.; Fort, B.; Meckley, M.; Antony, S.; Kohlhagen, G.; Pommier, Y.; Cushman, M. Synthesis and Anticancer Activity of Simplified Indenoisoquinoline Topoisomerase I Inhibitors Lacking Substituents on the Aromatic Rings. J.
Med. Chem. 2004, 47, 5651-5661.
Quote
My goal is to always mix scientific knowledge with passion because it affords an infinite number of solutions.
Industry Experience
Lastname
Morrell
Suffix
Ph.D.
Photo
Position
andrew.morrell@knobbe.com
Additional Languages
Start Date
Tuesday, June 1, 2010